tirzepatide mechanism of action for weight loss New Medical Advances. Exploring Products | by James J Busby Medical Weight Loss — Shen

Diabetic retinopathy: a signal in type-2 diabetes patients SUSTAIN-6, the cardiovascular outcomes trial of semaglutide in type-2 diabetes, found a significantly higher rate of retinopathy complications in the semaglutide group: a hazard ratio of 1.76 (95% CI 1.11 to 2.78) for vitreous haemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation

Online reports can show that people notice a symptom, but they cannot tell you whether the medicine caused it, whether the change would have happened anyway, or whether another factor was involved

Shorter Lifespan: Research consistently shows that high visceral fat is strongly linked to earlier mortality, even in people who are otherwise healthy

Significant weight reduction can lead to decreased skin elasticity, increased skin laxity, dryness, and subjective changes in skin texture

While the major SURMOUNT trials primarily examined weekly dosing protocols, emerging clinical evidence and real-world data support twice-weekly schedules as an effective alternative for patients who tolerate more frequent injections or experience better appetite suppression with this frequency

However, its important to remember that obesity is a chronic disease, and these are long-term treatments that may not be covered by insurance